Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns
Entity
UAM. Departamento de Biología MolecularPublisher
Elselvier Science BVDate
2014-12-01Citation
10.1016/j.bbadis.2014.09.004
Biochimica et Biophysica Acta - Molecular Basis of Disease 1842.12 (2014): 2448–2456
ISSN
0925-4439DOI
10.1016/j.bbadis.2014.09.004Funded by
Grants from Ministerio de Educación y Ciencia (SAF2011-23800), Fundación para la Investigación Médica Aplicada (FIMA) and UTE project CIMA, The Cardiovascular Network of Ministerio Sanidad y Consumo-Instituto Carlos III (RD06-0014/0037 and RD12/0042/0012), Comunidad de Madrid (S2010/BMD-2332) and EFSD-Novo Nordisk to F.M and UAM Grupo Santander to C.M and Wood-Whelan Research Fellowship from IUBMB to E.L. We also acknowledge institutional support from Fundación Ramón ArecesProject
Comunidad de Madrid. S2010/BMD-2332/INDISNETEditor's Version
http://dx.doi.org/10.1016/j.bbadis.2014.09.004Subjects
Cardiac hypertrophy; G protein-coupled receptors; GRK2; Heart failure; High fat diet; Insulin resistance; Biología y Biomedicina / BiologíaRights
© 2014 ElsevierEsta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Abstract
G protein-coupled receptor kinase 2 (GRK2) has recently emerged as a negative modulator of insulin signalling. GRK2
downregulation improves insulin sensitivity and prevents systemic insulin resistance (IR). Cardiac GRK2 levels are increased in
5
human heart failure, while genetically inhibiting GRK2 leads to cardioprotection in mice. However, the molecular basis underlying the
6
deleterious effects of GRK2 up-regulation and the beneficial effects of its inhibition in the heart are not fully understood. Therefore,
7
we have explored the interconnections among a systemic IR status, GRK2 dosage and cardiac insulin sensitivity in adult (9 month-old)
animals. GRK2+/- mice display enhanced cardiac insulin sensitivity and mild heart hypertrophy with preserved systolic function.
Cardiac gene expression is reprogrammed in these animals, with increased expression of genes related to physiological hypertrophy,
while the expression of genes related to pathological hypertrophy or to diabetes/obesity co-morbidities is repressed. Notably, we find
that cardiac GRK2 levels increase in situations where IR develops, such as in ob/ob mice or after high fat diet feeding. Our data
suggest that GRK2 downregulation/inhibition can help maintain cardiac function in the face of co-morbidities such as IR, diabetes or
obesity by sustaining insulin sensitivity and promoting a gene expression reprogramming that confers cardioprotection.
Files in this item
Google Scholar:Lucas, Elisa
-
Jurado-Pueyo, María
-
Fortuño, María A.
-
Fernández-Veledo, Sonia
-
Vila Bedmar, Rocío
-
Jiménez-Borreguero, Luis J.
-
Lazcano, Juan J.
-
Gao, Ehre
-
Gómez-Ambrosi, Javier
-
Frühbeck, Gema
-
Koch, Walter J.
-
Díez, Javier
-
Mayor Menéndez, Federico
-
Murga Montesinos, Cristina
This item appears in the following Collection(s)
- Producción científica de la UAM [20576]
Related items
Showing items related by title, author, creator and subject.